13/10/2021 - Institutional news
The Hospital del Mar Medical Research Institute is once again holding its annual meeting to update on the progress made and to highlight the talent of its researchers. After a year and a half marked by the Covid-19 pandemic, the Hospital del Mar Medical Research Institute (IMIM) has recovered its Scientific Retreat, the first face-to-face event since the outbreak of SARS-CoV-2. A new opportunity "to learn about the latest advances made by the institution's research groups, share experiences and seek new avenues for collaboration", as explained during the opening ceremony by the director of IMIM, Dr. Joaquín Arribas. The day got underway with an exceptional round table. Dr. Josep Tabernero, director of the Vall d'Hebron Institute of Oncology (VHIO) and head of the Medical Oncology Service of the Vall d'Hebron University Hospital, and Dr. Eduard Batlle, ICREA researcher at the Barcelona Institute for Research in Biomedicine (IRB), former IMIM researcher and current King Jaime I award winner, analyzed translational research, in a debate moderated by Dr. Jordi Camí, director of the Barcelona Biomedical Research Park (PRBB).
Més informació "The IMIM Scientific Retreat, an opportunity to promote research"
08/10/2021 - Institutional news
The IMIM Foundation announces one open position for a Recognised Researcher (R4) with the objective of incorporating an international leader researcher to one of the main research areas of IMIM: Cancer, Epidemiology and Public Health, Clinical Translation, Biomedical Informatics, or Neurosciences. Incorporation to the IMIM Foundation will be through a permanent full-time work contract. The mission of the job is to carry out research of excellence and to achieve effective transfer of this to the most important health problems in the population, observing, at all times, the Institute's Code of Good Practice and Code of Ethics.
05/10/2021 - General information
With this new group, the Carlos III Health Institute's Networked Biomedical Research Centre aims to unite Spain's scientific excellence in this field to enable better funding in emerging diseases, such as COVID-19, and other research areas, including antimicrobial resistance and HIV-AIDS, in which Hospital del Mar and IMIM researchers have a great deal of experience. The Infectious Pathology and Antimicrobial Research Group (IPAR) at the Hospital de Mar Medical Research Institute (IMIM) will form part of the new CIBER on Infectious Diseases. The purpose of this new group is to promote research in this field in Spain by offering new structural funding tools.
Més informació "Hospital del Mar and IMIM to participate in the new CIBER on infectious diseases"
1/10/2021 - Press release
Patients with chronic obstructive pulmonary disease (COPD) who also suffer from a blood iron deficiency significantly improve their physical fitness if they receive supplements of this mineral. This is a new approach to the disease, which has been validated by the first studies published in Spain in this field and the largest in the world, to date, involving 66 patients. The work, derived from the FACE-Ferinject Assessment study on improving Exercise Tolerance in patients suffering COPD and iron deficiency, was carried out by doctors and researchers in the Pneumology Department at Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) and has been published in the journals Archivos de Bronconeumología and Biomedicines.
Més informació "Iron supplements improve physical fitness and quality of life in COPD patients"
29/09/2021 - Institutional news
Doctors Juan Pablo Horcajada and Robert Güerri are part of this committee, which was officially constituted yesterday. This body will begin its work with 32 people associated with scientific knowledge from various professions and fields and will operate with independent criteria. Its task is to offer technical advice on different actions to be taken to control the pandemic. Yesterday, the Department of Health officially established the COVID-19 Scientific Advisory Committee, a body created to provide independent advice on the different pandemic-control actions in Catalonia. Among its 32 founding members is Dr. Juan Pablo Horcajada, head of the Infectious Diseases Service at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group (IPAR) at the Hospital del Mar Medical Research Institute (IMIM); In addition to Dr. Robert Güerri, section head of the Infectious Diseases Service and an IMIM researcher.
16/09/2021 - Press release
Older adults who are overweight or obese who stick most closely to the Mediterranean diet preserve their cognitive performance and even improve their abilities after three years, according to a study led by researchers at the Hospital del Mar Medical Research Institute and the CIBEROBN, published in the journal Clinical Nutrition. Memory improvements are proportional to the level of adherence to the Mediterranean diet, weight loss and increased physical activity. At the same time, these changes translate into improvements in people's quality of life. The work is based on the PREDIMED-PLUS trial and shows that women and people with less education gain less benefit on a cognitive level from this type of dietary intervention. This leads the researchers to support the personalization of these approaches in order to maximize the benefit.
Més informació "The Mediterranean diet helps improve cognitive function and memory"
15/09/2021 - Institutional news
Dr. Pedro Rocha is one of the nine people to receive an award from the European Society of Medical Oncology. In his case, this means joining the lung cancer team at Hospital del Mar led by Dr. Edurne Arriola. He will also take part in the research being carried out by this team at the Hospital del Mar Medical Research Institute in the field of small cell lung cancer. These ESMO Research Fellowship grants allow young doctors and researchers the opportunity to develop a research project in a European reference centre. As explained by Dr. Arriola, "The awarding of this grant establishes Hospital del Mar as a world-class centre of interest in the field of oncology." Dr. Rocha is currently working at the MD Anderson Cancer Centre at the University of Texas, in the United States.
13/09/2021 - General information
The editorial team of this prestigious publication, the third most important in respiratory medicine according to impact factor, has invited the consultant physician from the Pneumology Department and researcher at the Hospital del Mar Medical Research Institute, to collaborate with them. Dr. Esther Barreiro has joined the editorial team at the European Respiratory Society, as Associate Editor of the European Respiratory Journal (ERJ). Her role involves assisting the journal's senior editors to select potentially interesting manuscripts for publication, as well as inviting reviewers and providing advice on publication decisions. She will also write editorials for publication.
09/09/2021 - General information
A study lead by researchers from the Hospital del Mar Medical Research Institute (IMIM) and the Centre for Cellular and Molecular Biology of the Council Of Scientific And Industrial Research (CSIR) published in the Science Advances journal, shows for the first time how cholesterol can interfere with the function of a important receptor present in brain cells - the serotonin receptor. This finding is of great importance, as it allows to devise new ways to modulate those receptors, which in the future could lead to the development of new drugs to treat diseases of the central nervous system. Cholesterol is an essential component of the neuron membrane. Multiple proteins reside within those membranes, including GPCRs (G-protein coupled receptors). GPCRs are a large receptor family, encompassing serotonin receptors, which act as cellular receptors, detecting outside signals and transmitting towards the cell. Because of this, GPCRs are crucial for correct communications between cells.
12/08/2021 - Press release
A study led by doctors and researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), and CIBER Oncology (CIBERONC) has demonstrated the role a protein, neuregulin, plays in generating resistance to the most common treatment for HER2-positive breast cancer, one of the most aggressive types. The study, published in the journal Clinical Cancer Research, and in which leading Italian researchers Luca Gianni from the Fondazione Gianni Bonnadonna and Giampaolo Bianchini from the IRCCS Ospedale San Raffaele have collaborated, has identified that in patients with high levels of this protein, the success rate with the monoclonal antibody trastuzumab, the first-line drug, drops. Conversely, when combined with another monoclonal antibody, pertuzumab, the situation is reversed and full pathological response levels are restored.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
